Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 22.0x - 24.3x | 23.2x |
| Selected Fwd P/E Multiple | 25.8x - 28.5x | 27.2x |
| Fair Value | €14.42 - €15.94 | €15.18 |
| Upside | 11.0% - 22.6% | 16.8% |
| Benchmarks | - | Full Ticker |
| Lupin Limited | 50,025,700.0% | BSE:500257 |
| Abbott India Limited | 50,048,800.0% | BSE:500488 |
| Alembic Pharmaceuticals Limited | 53,357,300.0% | BSE:533573 |
| Zydus Lifesciences Limited | 53,232,100.0% | BSE:532321 |
| Alkem Laboratories Limited | 53,952,300.0% | BSE:539523 |
| Dr. Reddy's Laboratories Limited | - | DB:RDDA |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| 500257 | 500488 | 533573 | 532321 | 539523 | RDDA | |||
| BSE:500257 | BSE:500488 | BSE:533573 | BSE:532321 | BSE:539523 | DB:RDDA | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | 19.0% | -6.8% | 30.9% | 14.0% | 23.7% | ||
| 3Y CAGR | NM- | 21.0% | 3.8% | 26.4% | 9.6% | 33.9% | ||
| Latest Twelve Months | 71.4% | 17.8% | -5.3% | 18.0% | 20.6% | 1.5% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 3.8% | 17.9% | 11.8% | 18.7% | 14.7% | 14.6% | ||
| Prior Fiscal Year | 9.6% | 20.5% | 9.9% | 19.6% | 14.2% | 19.9% | ||
| Latest Fiscal Year | 14.5% | 22.1% | 8.7% | 19.5% | 16.7% | 17.4% | ||
| Latest Twelve Months | 14.5% | 22.1% | 8.7% | 19.5% | 16.7% | 17.4% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 16.3x | 42.7x | 19.8x | 13.4x | 21.2x | 12.1x | ||
| Price / LTM Sales | 3.9x | 10.3x | 2.8x | 4.1x | 4.4x | 3.4x | ||
| LTM P/E Ratio | 26.8x | 46.7x | 31.5x | 21.2x | 26.3x | 19.4x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | 21.2x | 26.8x | 46.7x | |||||
| Historical LTM P/E Ratio | 19.4x | 21.1x | 35.3x | |||||
| Selected P/E Multiple | 22.0x | 23.2x | 24.3x | |||||
| (x) LTM Net Income | 56,544 | 56,544 | 56,544 | |||||
| (=) Equity Value | 1,243,803 | 1,309,266 | 1,374,729 | |||||
| (/) Shares Outstanding | 832.1 | 832.1 | 832.1 | |||||
| Implied Value Range | 1,494.74 | 1,573.41 | 1,652.08 | |||||
| FX Rate: INR/EUR | 100.1 | 100.1 | 100.1 | Market Price | ||||
| Implied Value Range (Trading Cur) | 14.94 | 15.72 | 16.51 | 13.00 | ||||
| Upside / (Downside) | 14.9% | 21.0% | 27.0% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | 500257 | 500488 | 533573 | 532321 | 539523 | RDDA | |
| Value of Common Equity | 880,555 | 660,617 | 184,563 | 958,891 | 569,542 | 1,082,460 | |
| (/) Shares Outstanding | 456.7 | 21.2 | 196.6 | 1,006.2 | 119.6 | 832.1 | |
| Implied Stock Price | 1,928.10 | 31,088.90 | 938.95 | 952.95 | 4,763.45 | 1,300.85 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 100.07 | |
| Implied Stock Price (Trading Cur) | 1,928.10 | 31,088.90 | 938.95 | 952.95 | 4,763.45 | 13.00 | |
| Trading Currency | INR | INR | INR | INR | INR | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 100.07 | |